Close this search box.

Genomics investments deliver precision health for Canadians


Ottawa, ON

New pan-Canadian All for One initiative will increase equitable access to genome-wide sequencing for diagnosis and treatment of genetic disease.

The Genome Canada-led All for One precision health partnership launched today will advance a new standard of health care for Canadians, expanding access to genome-wide sequencing for diagnosis and treatment of life-threatening genetic diseases.

The $39 million All for One initiative includes $13 million in federal investment through Genome Canada and $26 million in co-funding from industry, health-care organizations, provincial and other partners brought in through six regional Genome Centres.

Advances in precision health—which harnesses the power of genome sequencing to diagnose and inform treatment of genetic conditions—are revolutionizing healthcare, but access to clinical genomic testing across Canada remains inconsistent.

With pan-Canadian reach and strong partnership from provincial and regional health services authorities, All for One will be a core building block of a coordinated human health genomics ecosystem in Canada, bridging clinical care and cutting-edge research. A foundational element of Genome Canada’s precision health leadership, All for One will also make a major contribution to Canada’s national rare disease strategy.

All for One is:

The launch of All for One follows the announcement last month of the final project in the initiative, funded through Ontario Genomics. This project will pilot an optimized clinical genome-wide sequencing service for patients with rare diseases in Ontario, delivered by CHEO and the Hospital for Sick Children (SickKids) in collaboration with the Ontario Ministry of Health. Currently, more than one third of Ontarians with a rare disease lack a genetic diagnosis, despite lengthy and costly investigations.

Explore All for One projects below


“Our government is ensuring that Canada is a leading force in the science of genomics because we know the positive impacts that will have on our healthcare systems. Through our investment in Genome Canada’s All for One initiative, we are leading the way and supporting partnerships to build a stronger system with more precise healthcare for all Canadians.”
– The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry

“Genomics-enabled precision health is a game-changer for patient care in Canada. The All for One precision health initiative will be a key pillar in a coordinated human health genomics ecosystem for Canadians. Genome Canada is proud to support this pan-Canadian collaboration, helping establish a new standard of care for patients with serious genetic disease, bringing the power of genomics into the doctor’s office and enabling life-saving research through genomic and clinical data sharing.”
– Dr. Rob Annan, President and CEO, Genome Canada

“Access to state-of-the-art genome-wide sequencing will be life-saving and transformative for Canadian patients, some of whom have been struggling for years to get a diagnosis. All for One opens the door for appropriate care and also opportunity for clinical trials and other interventions. Kudos to Genome Canada and all of the partners for continuing to put patients first.”
– Dr. Durhane Wong-Rieger, President & CEO, Canadian Organization for Rare Disorders

Learn more about the All for One-related projects

Related links

About Genome Canada

Genome Canada is a national not-for-profit organization addressing Canada’s greatest challenges and opportunities through research and innovation in genomics and associated biosciences. With a 21-year track record of impact across sectors, a pan-Canadian network of six regional Genome Centres, and strong partnerships across the public, private, non-profit and academic sectors at home and internationally, we translate research into real-world impact in health, climate action and food security.

Media contact

Nicola Katz
Director, Communications
Genome Canada
Cell: 613-297-0267

Quick facts

Media contact